EMEA-001095-PIP03-19
Key facts
| Invented name |
Tysabri
|
| Active substance |
natalizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0123/2020
|
| PIP number |
EMEA-001095-PIP03-19
|
| Pharmaceutical form(s) |
Solution for injection in pre-filled syringe
|
| Condition(s) / indication(s) |
Treatment of multiple sclerosis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Biogen Idec Ltd
Tel. +01 628501000 |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|